

Estimation of Serum Interleukin-6 level as a Useful Marker for Clinical Severity of Sickle Cell Disease among Sudanese Patients

Alaaeddin M.Elzubeir^{1*}, Anna Alobied², Hala Halim², Mayadah Awad², Somia Elfaki², Maysoon Mohammed², Osman A. Saddig²

¹Department of Haematology and Immunohaematology, FMLs, Sudan International University - Sudan

²Department of Haematology and Immunohaematology, FMLs, University of Khartoum - Sudan

Accepted 15 May 2017, Available online 31 May 2017, Vol.5 (May/June 2017 issue)

Abstract

Background: Sickle cell disease (SCD) is an inherited disease characterized by a complex and varied physiopathology and exhibits wide clinical diversity. SCA's variability and pose significant management challenges to all medical staff

Objectives: We aimed in this study to correlate between serum interleukin-6 level and the clinical severity events of SCD in Sudanese Patients

Method: Case control study conducted on 133 patients with Sickle cell disease were collected and level of serum IL-6 were determined by ELISA and compared to 93 apparently healthy individuals as Control group.

Result: There was significant association between elevation in serum IL-6 and development of complications in SCD, Chi squared (χ^2) = 0.000 ($P < 0.05$).

Conclusion: These findings indicated that serum level of IL-6 may contribute to susceptibility to many crisis and may use as useful marker for early broadcasting tool for SCD crisis.

Keywords: Sickle Cell Disease, Severity, Serum IL-6, SCD Marker

Introduction

Sickle cell anaemia (genotype SS) causes moderate anaemia resulting both from haemolysis and from the reduced oxygen affinity of haemoglobin S.^{1,2} The main clinical disability arises from repeated episodes of vascular occlusion by sickled red cells resulting in acute crises and eventually in end-organ damage.^{3,4}

The clinical severity of sickle cell anaemia is extremely variable. This is partly due to the effects of inherited modifying factors, such as interaction with thalassemia or increase synthesis of Hb F and partly to socioeconomic conditions and other factors that influence general health.⁵ Interleukin-6 (IL-6) is an endogenous chemical which is active in inflammation. Besides being an immune protein, it is also a pyrogenic, and is responsible for fever in autoimmune, infectious or non-infectious disease⁶. It is produced in the body, wherever there is inflammation, either acute or chronic. Interleukin-6 is implicated in a host of chronic disease conditions associated with inflammation; significantly increased values of IL-6 and IL-2 were found⁷.

Studies has demonstrated increased serum levels of some of the acute phase proteins in patients during the steady state of sickle cell disease. This may be a result of a subclinical vaso-occlusion which in turn leads to a covert inflammatory response. Cytokines, and in particular IL-6, produced after this response, seem to be responsible for the high levels of acute phase proteins in the steady state of this disease.^{8,9} In patients with childhood sickle cell disease (SCD) serum interleukin-6 (IL-6) levels were measured during the steady (healthy) state of disease. Results revealed significantly higher circulating levels of IL-6 in the SCD patients (60 +/- 7 pg/ml) compared with the healthy controls (12 +/- 5 pg/ml). The impact of high circulating levels of IL-6 may be deleterious to humoral and cell-mediated immune functions in SCD, with resultant heightened risk for morbidity.^{10,11}

Material and Methods

This is a descriptive analytical case control facility based study, conducted at Dr. Gaafar Ibn-Auf Paediatric Tertiary Hospital, as a part of previous work started from March /2016 up to April /2017. The local ethics committee and ministry of health approved the research conducted in accordance with WMA Declaration of Helsinki (2008).

*Corresponding author's ORCID ID: 0000-0000-0000-0000

DOI: <https://doi.org/10.14741/ijmcr/v.5.3.20>

Subject

Study population was 133 patients with Sickle cell disease regardless to age, gender and ethnic group. Clinical data was collected by a questionnaire, a recording form and an authorized clinician who carry out the clinical examination. After informed consent, a venous blood sample (2.5ml) was collected into EDTA container (whole blood) for CBC using Sysmex (KX 21N) and other 2.5ml of venous blood was collected into plain container for serum IL6 level detection using ELISA (STAT FAX-2600) and IL6 kits (Bio legend IL6 human cytokine ELISA).

Interleukin-6 Assay

Human interleukin-6 enzyme-linked immunosorbent assay (ELISA; STAT FAX-2600) was utilized to measure serum IL-6 levels. In summary of method, the captured antibody was coated to the plate, and the standards were reconstituted as directed. After adding plate reagent to each well, 50 pi standards or serum samples in duplicate was added and the plate was incubated for 1 h at 37°C. Unbound material was then removed by aspiration and washing. Next conjugate reagent was added and the plate was incubated for 30 minutes. After incubation, unbound labeled antibody in the conjugate reagent was then removed by aspiration and washing. The bound IL-6 was quantified by an enzymatic reaction, resulting in a detectable color change, using the ELISA reader (Thermo Lab System, Finland), set at 450 nm. To estimate the amount of IL-6 in the serum, a standard curve was constructed utilizing the known standard concentrations. Concentrations of samples were determined by referring to the standard curve and expressed as pg/ml. The detection limit was 5 pg/ml.

Statistical analysis

Statistical methods Concentrations are expressed as mean titers (M ± Standard error of the mean. Statistical analysis of the mean titers of the serum IL-6 levels was performed utilizing an independent t test with significant P.value (>0.05).

Results

All medical and clinical data of the subjects were documented before IL-6 level estimation. The mean age of each group was included in the range 1 to 37 years; SCD duration was about 7.2 years as a mean. Different clinical severity states compared hematological values as showed in (Table 1). Serum level of IL-6 show high diversity between Patients’ and healthy individual’s results as control sample for serum IL-6 levels as showed in figure1.




Figure 1: A case and control IL-6 serum level estimation by ELISA technique, as described in Materials and Methods. The ranges of individual levels were as follows: SCD (35-300 pg/ml) and normal controls (5-23 pg/ml)

Table 1: Clinical Severity of Sickle Cell Disease among study population

Clinical Data		Severity of Disease			Total	P.value
		Mild	Moderate	Severe		
Gender	Female	7	23	46	76	0.456
	Male	7	12	38	57	
Age (mean) years		7.2	8.2	6.8	7.2	0.001
Stroke		2	18	67	87	0.000
Sequestration/vasoocclusion		4	21	81	106	0.000
Hemolytic Crisis		14	35	84	133	*a
Leg ulcer		0	1	3	4	0.768
Musculo-skeletal pain		9	35	79	123	0.000
Acute Chest Syndrome		8	23	76	107	0.001

*Bolted values indicate statistical significance.*a No statistics are computed because Hemolytic Crisis is a constant

Table 2: Relationship between laboratory findings and disease severity

Laboratory parameters	Mild disease N=14 (mean)	Moderate disease N=35 (mean)	Severe disease N=84 (mean)	P
IL-6 level (pg/ml)	35	69	380	0.000
TWBCs (×10 ⁹ /L)	12.2	13.8	15.1	0.007
Neutrophils (×10 ⁹ /L)	6.8	7	7.5	0.000
Lymphocyte(×10 ⁹ /L)	5.9	5.7	5.1	0.001
RBCs (×10 ¹² /L)	2.6	2.7	2.3	0.045
Haemoglobin (g/dL)	7.0	8.2	7.3	0.000
Haematocrit (%)	22.7	22.9	21.3	0.034
MCV(fl)	89	86.3	94	0.017
MCH(pg)	32.4	30.7	34.3	0.000
MCHC(g/dL)	35.8	35.8	36.5	0.001
Platelet(×10 ⁹ /L)	572.6	450	525	0.044

N: Number of cases, TWBCs, total white blood cells count; RBCs, red blood cells count; MCV, mean cell volume; MCH, mean cell haemoglobin; MCHC, mean cell haemoglobin concentration; Bolted values indicate statistical significance.

Discussion

SCD, particularly in the homozygous state, may be characterized by significant morbidity and early mortality. Individuals affected by this hemoglobinopathy exhibit many of the manifestations associated with immunodeficiency disorders. The data reported are representative of one phase of a comprehensive evaluation of SCD as a model for immunosuppression. Interleukin-6 is a multifunctional regulatory cytokine that contributes to the immune response, acute-phase reactions, and hematopoiesis. Upon stimulation with antigen, B cells proliferate and differentiate to antibody-forming plasma cells under the influence of various cytokines.¹² IL-6 acts on activated and proliferating B cells and induces their final maturation into antibody-forming plasma cells. Abnormal IL-6 production may play a significant role in a number of diseases, such as autoimmune diseases, chronic inflammation, and lymphoid malignancies, that may be associated with certain viruses.¹³ Recent examples characterize cytokines involved in type 1 and type 2 immune responses.^{14,15} In the type 1 pattern, IL-2 and interferon- γ (IFN) are autocrine growth factors. IL-2 facilitates helper T cells in their IFN- γ -mediated activation of macrophages (cell-mediated immunity). In type 2, IL-4 and IL-6 are autocrine growth factors promoting suppressor T cells in tilting the immune response toward humoral immunity. IL-6 is considered a type 2 cytokine and inherently suppresses cell-mediated immunity (CMI). Shearer and associates at the National Cancer Institute have shown that a strong CMI response with a type 1 cytokine profile is a better protector against human immunodeficiency virus infection than are strong antibody response and type 2 cytokine profile.¹⁵ Elevated circulating levels of IL-6 in healthy SCD patients may actually affect both CMI and humoral functions. In our study we found that IL-6 is highly elevated in proportion to the different severity states of SCD, compared with control group.

Conclusion

In summary, the levels of IL-6 in the different clinical states of SCD may represent contribution in exacerbation of severity of SCD, with resultant increased risk crisis and eventually increase in mortality and morbidity rates.

Acknowledgement

We are so acknowledged to our supervisors who supplied us and guided us through this epic work; Gaafar Ibn-Auf Paediatric Tertiary Hospital; University of Khartoum, Faculty of Medical Laboratory Sciences and Institute of Endemic Diseases, Sudan University of Science and Technology for their permissions to carry out this work.

References

- [1]. Martin H. Steinberg, Bernard G. Forget, Douglas R. Higgs, David J. Weatherall: Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management
- [2]. Beyer JE, Simon LE. Home treatment of pain for children and adolescents with sickle cell disease. *Pain Manage Nurs* 2004; 5:126-135
- [3]. Lewis, S., Bain, B. And Bates, I. 2006. *Dacie and Lewis: Practical Hematology*, Churchill Livingstone
- [4]. Hebbel RP, Eaton JW, Balasingam M, Steinberg MH. Spontaneous oxygen radical generation by sickle erythrocytes. *J. Clin. Invest.* 1982; 70:1253-1259
- [5]. Nessar Ahmed, Maureen Dawson, Chris Smith, Ed Wood: *Biology of Disease*
- [6]. Richard Coico, Geoffrey Sunshine: *Immunology: A Short Course*
- [7]. Simpson RJ1, Hammacher A, Smith DK, Matthews JM, Ward LD. Interleukin-6: structure-function relationships. *Protein Sci.* 1997 May; 6(5):929-55.
- [8]. Bourantas KL1, Dalekos GN, Makis A, Chaidos A, Tsiara S, Mavridis A. *Eur J Haematol.* Acute phase proteins and interleukins in steady state sickle cell disease. 1998 Jul; 61(1):49-54.
- [9]. Abiodun Mathias Emokpae, Uadia Patrick Ojiefio, Kuliya-Gwarzo Aisha, Antioxidant Enzymes and Acute Phase Proteins Correlate with Marker of Lipid Peroxide in Adult Nigerian Sickle Cell Disease Patients, *Iranian Journal of Basic Medical Sciences* 2010 Autumn; 13(4):177-182
- [10]. Svarch E, Hernandez P, Ballester JM. Sickle cell disease in cuba; general review, *Institute de Hematologia en Immunologia (IHI) la Havana, Cuba* 2001
- [11]. Taylor SC1, Shacks SJ, Mitchell RA, Banks A. , Serum interleukin-6 levels in the steady state of sickle cell disease, *J Interferon Cytokine Res.* 1995 Dec;15(12):1061-4.
- [12]. Kishimoto, T., and Hirano, T. (1988). Molecular regulation of B lymphocyte response. *Annu. Rev. Immunol.* 6,485.
- [13]. Hirano, T. (1992). Interleukin-6 and its relationship to inflammation and disease. *Clin. Immunol. Immunopathol.* 62, S60.
- [14]. Scott, P., and Kaufman, S.H.E. (1991). The role of T cell subsets and cytokines in regulation of infection. *Immunol. Today* 12,346.
- [15]. Shearer, G. (1994). Type 1 helper T-cell response: a leader in HIV control. *Clin. Immunol. Spectrum* 6(3), 1